 | • レポートコード：MRC2212A031 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、230ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の調査レポートでは、世界の持続血液グルコースモニタリングシステム市場規模が2021年の3,867.19百万ドルから、2022年に4,171.37百万ドルまで達すると予測しています。また今後、年平均8.04%成長し、2027年には6,151.31百万ドルまで拡大する見通しです。本調査レポートでは、持続血液グルコースモニタリングシステムの世界市場を調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別（持続血糖モニタリング（CGM）システム、自己血糖モニタリングシステム）分析、構成部品別（CGMモニター、CGM送信機、グルコースセンサー）分析、検査箇所別（代替箇所検査、指先検査）分析、医療機関別（病院・診療所、セルフ/在宅医療）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目を掲載しています。こちらの調査レポートではA Menarini Diagnostics Ltd.、Abbott Laboratories、B. Braun Melsungen AG、Bayer AG、Dexcom, Inc.、Echo Therapeutics, Inc、Eli Lilly and Company、F. Hoffmann-La Roche Ltd、GlySens Incorporated、Integrity Applications Inc、Johnson & Johnson Services, Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の持続血液グルコースモニタリングシステム市場規模：製品別 - 持続血糖モニタリング（CGM）システムの市場規模 - 自己血糖モニタリングシステムの市場規模 ・世界の持続血液グルコースモニタリングシステム市場規模：構成部品別 - CGMモニターの市場規模 - CGM送信機の市場規模 - グルコースセンサーの市場規模 ・世界の持続血液グルコースモニタリングシステム市場規模：検査箇所別 - 代替箇所検査における市場規模 - 指先検査における市場規模 ・世界の持続血液グルコースモニタリングシステム市場規模：地域別 ・世界の持続血液グルコースモニタリングシステム市場規模：医療機関別 - 病院・診療所における市場規模 - セルフ/在宅医療における市場規模 ・世界の持続血液グルコースモニタリングシステム市場規模：地域別 - 南北アメリカの持続血液グルコースモニタリングシステム市場規模 アメリカの持続血液グルコースモニタリングシステム市場規模 カナダの持続血液グルコースモニタリングシステム市場規模 ブラジルの持続血液グルコースモニタリングシステム市場規模 ... - アジア太平洋の持続血液グルコースモニタリングシステム市場規模 日本の持続血液グルコースモニタリングシステム市場規模 中国の持続血液グルコースモニタリングシステム市場規模 インドの持続血液グルコースモニタリングシステム市場規模 韓国の持続血液グルコースモニタリングシステム市場規模 台湾の持続血液グルコースモニタリングシステム市場規模 ... - ヨーロッパ/中東/アフリカの持続血液グルコースモニタリングシステム市場規模 イギリスの持続血液グルコースモニタリングシステム市場規模 ドイツの持続血液グルコースモニタリングシステム市場規模 フランスの持続血液グルコースモニタリングシステム市場規模 ロシアの持続血液グルコースモニタリングシステム市場規模 ... - その他地域の持続血液グルコースモニタリングシステム市場規模 ・競争状況 ・企業情報 |
The Global Continuous Blood Glucose Monitoring Systems Market size was estimated at USD 3,867.19 million in 2021 and expected to reach USD 4,171.37 million in 2022, and is projected to grow at a CAGR 8.04% to reach USD 6,151.31 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Continuous Blood Glucose Monitoring Systems to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Continuous Glucose Monitoring Systems and Self-Monitoring Blood Glucose Systems. The Continuous Glucose Monitoring Systems is further studied across Receivers, Sensors, and Transmitters. The Self-Monitoring Blood Glucose Systems is further studied across Blood Glucose meters, Lancets & Lancing Devices, and Testing strips.
Based on Component, the market was studied across CGM Monitor, CGM Transmitter, and Glucose Sensor.
Based on Testing Site, the market was studied across Alternate Site Testing and Fingertip testing.
Based on Patient Care Setting, the market was studied across Hospital & Clinics and Self/Home Care.
Based on Application, the market was studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Continuous Blood Glucose Monitoring Systems market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Continuous Blood Glucose Monitoring Systems Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Continuous Blood Glucose Monitoring Systems Market, including A Menarini Diagnostics Ltd., Abbott Laboratories, B. Braun Melsungen AG, Bayer AG, Dexcom, Inc., Echo Therapeutics, Inc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlySens Incorporated, Integrity Applications Inc, Johnson & Johnson Services, Inc., LifeScan IP Holdings, LLC, Medtronic PLC, Novo Nordisk A/S, OrSense Ltd, PHC Holdings Corporation, Senseonics Holdings, Inc., and Tandem Diabetes Care, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Continuous Blood Glucose Monitoring Systems Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Continuous Blood Glucose Monitoring Systems Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Continuous Blood Glucose Monitoring Systems Market?
4. What is the competitive strategic window for opportunities in the Global Continuous Blood Glucose Monitoring Systems Market?
5. What are the technology trends and regulatory frameworks in the Global Continuous Blood Glucose Monitoring Systems Market?
6. What is the market share of the leading vendors in the Global Continuous Blood Glucose Monitoring Systems Market?
7. What modes and strategic moves are considered suitable for entering the Global Continuous Blood Glucose Monitoring Systems Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Need an effective way to detect drastic changes in blood glucose for increasing diabetes cases
5.1.1.2. Benefits associated with continuous blood glucose monitoring systems over Point-of-Care glucometers
5.1.1.3. Increasing awareness through government initiatives for the product
5.1.2. Restraints
5.1.2.1. Accuracy and precision on measurement and cost associated with sensor lifetime
5.1.3. Opportunities
5.1.3.1. Growing adoption rate of continuous blood glucose monitoring systems in home healthcare
5.1.3.2. Potential undiagnosed patient population
5.1.4. Challenges
5.1.4.1. Instability of patterns and reproducibility to results
5.2. Cumulative Impact of COVID-19
6. Continuous Blood Glucose Monitoring Systems Market, by Product
6.1. Introduction
6.2. Continuous Glucose Monitoring Systems
6.3.1. Receivers
6.3.2. Sensors
6.3.3. Transmitters
6.3. Self-Monitoring Blood Glucose Systems
6.4.1. Blood Glucose meters
6.4.2. Lancets & Lancing Devices
6.4.3. Testing strips
7. Continuous Blood Glucose Monitoring Systems Market, by Component
7.1. Introduction
7.2. CGM Monitor
7.3. CGM Transmitter
7.4. Glucose Sensor
8. Continuous Blood Glucose Monitoring Systems Market, by Testing Site
8.1. Introduction
8.2. Alternate Site Testing
8.3. Fingertip testing
9. Continuous Blood Glucose Monitoring Systems Market, by Patient Care Setting
9.1. Introduction
9.2. Hospital & Clinics
9.3. Self/Home Care
10. Continuous Blood Glucose Monitoring Systems Market, by Application
10.1. Introduction
10.2. Gestational Diabetes
10.3. Type 1 Diabetes
10.4. Type 2 Diabetes
11. Americas Continuous Blood Glucose Monitoring Systems Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Continuous Blood Glucose Monitoring Systems Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Continuous Blood Glucose Monitoring Systems Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. A Menarini Diagnostics Ltd.
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Abbott Laboratories
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. B. Braun Melsungen AG
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Bayer AG
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Dexcom, Inc.
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Echo Therapeutics, Inc
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Eli Lilly and Company
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. F. Hoffmann-La Roche Ltd
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. GlySens Incorporated
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Integrity Applications Inc
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Johnson & Johnson Services, Inc.
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. LifeScan IP Holdings, LLC
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Medtronic PLC
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Novo Nordisk A/S
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. OrSense Ltd
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. PHC Holdings Corporation
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Senseonics Holdings, Inc.
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. Tandem Diabetes Care, Inc.
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing